Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
August 05, 2009 08:05 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - August 5, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) and Marshall Edwards, Inc. (NASDAQ: MSHL) have
concluded a license agreement for...
Novogen Director Retires
July 30, 2009 08:00 ET
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - July 30, 2009) - The Board of Novogen Limited (ASX: NRT)
(NASDAQ: NVGN) has received and accepted the resignation of Mr. Peter B.
Simpson as a Director of the...
Chelsea Therapeutics Appoints William Rueckert to Board of Directors
July 28, 2009 07:25 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., July 28, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that William D. Rueckert has been appointed to the Company's Board of Directors,...
Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
July 07, 2009 08:00 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - July 7, 2009) - Researchers at the
Malaghan Institute of Medical Research in Wellington, New Zealand have
found that abnormally proliferating human...
Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
June 17, 2009 08:30 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - June 17, 2009) - The Independent Data Monitoring Committee
(IDMC) created to oversee the conduct of the Phase III OVArian TUmor
REsponse (OVATURE) Trial, which convened...
Novogen's NV-128 Targets the mTOR Pathway to Block Differentiation and Induce Cell Death in Ovarian Cancer Stem Cells
April 20, 2009 08:00 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 20, 2009) - Data presented
yesterday at the Annual Meeting of the American Association for Cancer
Research in Denver has demonstrated that...
Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
April 14, 2009 08:20 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 14, 2009) - Marshall Edwards,
Inc., (NASDAQ: MSHL) today announced that it will be undertaking an
un-blinded analysis of the data from its...
Board Changes at Novogen Limited Announced
March 23, 2009 10:46 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 23, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William
D. Rueckert to its Board of...
Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
March 19, 2009 13:07 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 19, 2009) - Marshall Edwards, Inc.
(NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the
Board of Directors of the...
Novogen's NV-128 Targets the mTOR Pathway to Induce Cell Death in Epithelial Ovarian Cancer Stem Cells
March 18, 2009 11:16 ET
|
Novogen, Limited
NEW CANAAN, CT--(Marketwire - March 18, 2009) - NV-128, a Novogen, Ltd. (ASX: NRT) (NASDAQ: NVGN) compound, induced cell death in ovarian cancer stem cells in a
dose-dependent manner. The study...